Missed our first session? Join us tomorrow for the second session in our series exploring perioperative immunotherapy for resectable, locally advanced HNSCC. Gain practical insights into emerging clinical evidence, treatment sequencing, and case-based decision-making. Register now: ow.ly/rK5S50ZBA4L A CME/CE-accredited activity developed by GLC. #HNSCC #Oncology #Immunotherapy #CME

The 22nd Women's Health Annual Visit is coming to Pasadena. Join co-chairs Barbara Dehn , NP, and Anita L. Nelson, MD, plus expert faculty on November 13 at the Pasadena Convention Center for a full day of evidence-based education in women's health. Register now: reachmd.com/u/20116 #WHAV2026 #WomensHealth #MedicalEducation #CME #OBGYN #Pasadena

Over the years, the Women's Health Annual Visit (WHAV) has consistently brought together leading faculty to discuss pressing issues in women's health and present the latest data in clinical care. 2026 is no exception. This year, WHAV will feature a multidisciplinary group of speakers, each sharing cutting edge insights that clinicians can apply in their own practice immediately. Register for a spot before it's too late! Grab a seat for NYC: Sign up to attend in Pasadena: #WHAV2026 #WomensHealth #MedicalEducation #CME

How are TROP2-directed antibody-drug conjugates influencing treatment considerations for patients with EGFR-mutated advanced NSCLC after progression on frontline EGFR-TKI therapy? Join expert faculty for a live webinar series examining the evolving clinical evidence supporting TROP2-directed ADCs in the post-TKI setting. Through expert discussion and case-based learning, participants will explore emerging data that may influence treatment sequencing, discover how to identify appropriate candidates based on clinical and molecular characteristics, and review proactive strategies for monitoring and managing class-specific toxicities. Register to gain insights on integrating TROP2-directed ADCs into personalized treatment plans as this therapeutic landscape continues to evolve: ow.ly/LZAR50ZSRvY A CME/CE-accredited activity developed by GLC. #LungCancer #NSCLC #ThoracicOncology #Oncology #CancerCare #MedicalEducation

LAST CHANCE to register for the last session of our webinar series on first-line management of KRAS G12C–mutated advanced NSCLC. Hear expert discussion on biomarker testing, treatment sequencing, and clinical trial readiness. Register here: ow.ly/Gp8G50ZAI2n A CME/CE-accredited activity developed by GLC. #LungCancer #NSCLC #MedEd

The treatment landscape for KRAS G12C–mutated advanced NSCLC is advancing quickly. How can we close the gap between emerging biology and everyday practice? Gerard A. Silvestri, MD, MS will examine biomarker testing, first-line treatment selection, and strategies to prepare eligible patients for clinical trials in KRAS G12C–mutated advanced NSCLC in this upcoming live virtual broadcast: "Closing the Gap in First-Line Treatment of KRAS G12C–Mutated Advanced NSCLC: From Biology to Bedside Decisions and Trial-Ready Care" 🗓️ Tuesday, September 30, 2026 🕟 4:30–5:15 PM EDT Save your seat: ow.ly/qY3x50ZPTh1 A CME/CE-accredited activity developed by GLC. #LungCancer #NSCLC #MedEd

What did clinicians value most at WHAV 2025? When last year's chair, Dr. Barbara Dehn, spoke with attendees about their favorite parts of the conference, two themes came up again and again. The first was practicality. Clinicians told Dr. Dehn that the pearls they picked up were ones they could bring straight back to their practice. The second was access. Attendees valued being able to connect with faculty 1-on-1 to talk about complicated cases. Good news—the cutting-edge clinical pearls and expert conversations are back! Grab your spot for WHAV 2026 now. Get tickets for NYC: ow.ly/Bl2H50ZQkv8 Save your spot in Pasadena: ow.ly/Cs7m50ZQkxH

How are evolving treatment strategies informing CLL/SLL care? Join distinguished faculty Jennifer R. Brown, MD, PhD, Shuo Ma, MD, Mazyar Shadman, MD, MPH for this CME-certified symposium focusing on fixed-duration versus continuous therapy, patient-specific treatment considerations, and emerging evidence that may influence future management approaches. Reserve your spot: ow.ly/g8Ja50ZNzQu A CME/CE-accredited activity developed by GLC. #CLL #SLL #OncologyEducation #Hematology #MedEd

When managing moderate to severe atopic dermatitis, how do you approach treatment escalation? Join a live virtual webinar tomorrow to review disease burden, treatment selection, and individualized care. Save your spot: ow.ly/2RnC50ZKXsp A CME/CE-accredited activity developed by GLC. #AtopicDermatitis #Dermatology #MedEd

How do you apply biomarker results to treatment planning in advanced ovarian cancer across different clinical scenarios? Last chance to join expert faculty for a live tumor board as they examine interactive patient cases, discuss biomarker-informed treatment approaches, review treatment sequencing considerations, and share practical strategies for managing adverse events. Reserve your spot: ow.ly/N4KW50ZtAMi #OvarianCancer #Oncology #TumorBoard #MedEd

Missed WCLC LIVE? Our WCLC 2026 satellite symposium on advanced squamous #NSCLC after chemoimmunotherapy progression is available virtually. Discover insights from leading faculty on resistance mechanisms, CTLA-4-targeted strategies, and treatment sequencing. Don't miss these expert perspectives. Register today! Save your seat: ow.ly/hMTR50ZPj13 A CME/CE-accredited activity developed by GLC. #ThoracicOncology #Oncology #WCLC2026

How do biomarker findings influence treatment decisions across the ovarian cancer continuum? Join expert faculty for a can't-miss LIVE virtual tumor board featuring interactive case discussions and practical clinical insights. "Treatment Decisions That Matter: Live Tumor Board in Advanced Ovarian Cancer" 🗓️ September 24, 2026 | 🕞 3:30–4:30 PM ET Ritu Salani, MD and Kathleen N. Moore, MD, MS will explore biomarker testing strategies and their role in patient selection, treatment sequencing, and individualized care. They'll also discuss the latest evidence supporting PARP inhibitors, immunotherapy, and antibody-drug conjugates as well as adverse event monitoring and management. Don't miss out! Save your spot now: ow.ly/Sbkq50ZPLKg #OvarianCancer #Oncology #TumorBoard #MedEd

What guides your approach to treatment escalation in moderate to severe atopic dermatitis? Join a live virtual webinar on September 24 to discuss disease burden, treatment options, and individualized care strategies. Register here: ow.ly/7uFX50ZKXjl A CME/CE-accredited activity developed by GLC. #AtopicDermatitis #Dermatology #MedEd

Treatment selection and sequencing remain important considerations across the CLL/SLL care continuum. Join this CME-certified symposium for a discussion of frontline and relapsed/refractory management strategies, prognostic testing, and emerging therapeutic approaches. Register: ow.ly/9KXb50ZNzNj A CME/CE-accredited activity developed by GLC. #CLL #SLL #Hematology #Oncology #MedEd

Our latest live cardiovascular broadcast, PSVT Without the Panic: Structured Care That Works, has one final date left! Hear Brian P. Rose, PA-C, MPH, AACC, Jennifer Carlquist, PA-C, and @sean_pokorney , MD, MBA, discuss practical approaches to identifying PSVT, overcoming diagnostic challenges, developing outpatient management strategies, and reducing unnecessary emergency department utilization. Join the conversation live: reachmd.com/u/19502 #Cardiology #Electrophysiology #Arrhythmia #PSVT #CME

Join the discussion on first-line care, treatment sequencing, and trial-ready strategies for patients with KRAS G12C–mutated advanced NSCLC. Register now: ow.ly/FsSW50ZAHZq A CME/CE-accredited activity developed by GLC. #LungCancer #NSCLC #CME

Tomorrow, join a live session where Marc Oliva will discuss perioperative immunotherapy for resectable, locally advanced HNSCC. The program will highlight clinical trial evidence, treatment sequencing, and case-based learning. Register now: ow.ly/Wjir50ZBzXN A CME/CE-accredited activity developed by GLC. #HNSCC #Oncology #Immunotherapy #CME

Tomorrow: Join leading faculty for a live discussion on emerging treatment frontiers in advanced squamous #NSCLC after chemoimmunotherapy failure. Gain practical insights through clinical evidence review and case-based perspectives. Last chance to register: ow.ly/QZ5m50ZAIBL A CME/CE-accredited activity developed by GLC. #Oncology #WCLC2026

Our understanding of FSGS continues to evolve. From the increasing importance of genetic causes in children to the classification of primary, genetic, and maladaptive FSGS, these insights are shaping how clinicians approach diagnosis and management: ow.ly/hBLX50ZFbUj

Women’s health is evolving fast, with new treatments, updated guidelines, and important conversations constantly emerging. WHAV 2026 offers a community-driven, collaborative environment where clinicians can explore the latest advances in women’s health and engage directly with expert faculty and their peers. Don’t miss the conversation. Claim your spot at WHAV 2026 today. Register for the NYC event: ow.ly/yQzF50ZLHys Sign up to attend in Pasadena: ow.ly/F0Vq50ZLHyw #WHAV2026 #WomensHealth #WomensHealthcare #WomensHealthEducation #HealthcareProfessionals #MedicalEducation #ClinicalEducation #HCPs